Accéder au contenu
MilliporeSigma
  • Histone methylation levels correlate with TGFBIp and extracellular matrix gene expression in normal and granular corneal dystrophy type 2 corneal fibroblasts.

Histone methylation levels correlate with TGFBIp and extracellular matrix gene expression in normal and granular corneal dystrophy type 2 corneal fibroblasts.

BMC medical genomics (2015-11-11)
Yong-Sun Maeng, Ga-Hyun Lee, Seung-Il Choi, Kyu Seo Kim, Eung Kweon Kim
RÉSUMÉ

TGFβ1-induced expression of transforming growth factor β-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy). Although some key transcription factors are known, the epigenetic mechanisms modulating TGFBIp and ECM expression remain unclear. We examined the role of chromatin markers such as histone H3 lysine methylation (H3Kme) in TGFβ1-induced TGFBIp and ECM gene expression in normal and GCD2-derived human corneal fibroblasts. Wild-type (n = 3), GCD2-heterozygous (n = 1), and GCD2-homozygous (n = 3) primary human corneal fibroblasts were harvested from human donors and patients prepared. Microarray and gene-expression profiling, Chromatin immunoprecipitation microarray analysis, and Methylated DNA isolation assay-assisted CpG microarrays was performed in Wild-type and GCD2-homozygous human cells. Transcription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus. TGFβ1 increased the expression of TGFBIp and the ECM-associated genes connective tissue growth factor, collagen-α2[Ι], and plasminogen activator inhibitor-1 in normal corneal fibroblasts. Increased levels of gene-activating markers (H3K4me1/3) and decreased levels of repressive markers (H3K27me3) at the promoters of those gene accompanied the changes in expression. TGFβ1 also increased recruitment of the H3K4 methyltransferase MLL1 and of SET7/9 and also the binding of Smad3 to the promoters. Knockdown of both MLL1 and SET7/9 significantly blocked the TGFβ1-induced gene expression and inhibited TGFβ1-induced changes in promoter H3K4me1/3 levels. Those effects were very weak, however, in GCD2-derived corneal fibroblasts. Taken together, the results show the functional role of H3K4me in TGFβ1-mediated TGFBIp and ECM gene expression in corneal fibroblasts. Pharmacologic and other therapies that regulate these modifications could have potential cornea-protective effects for granular corneal dystrophy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Diméthylsulfoxyde, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Diméthylsulfoxyde, ACS reagent, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, for molecular biology
Sigma-Aldrich
Diméthylsulfoxyde, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Diméthylsulfoxyde, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Diméthylsulfoxyde, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Diméthylsulfoxyde, anhydrous, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
Diméthylsulfoxyde, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Diméthylsulfoxyde, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
Diméthylsulfoxyde, PCR Reagent
Sigma-Aldrich
Diméthylsulfoxyde, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
Dimethyl sulfoxide solution, 50 wt. % in H2O
Sigma-Aldrich
Anticorps anti-monométhyl-histone H3 (Lys4), Upstate®, from rabbit
Sigma-Aldrich
8-Octanoyloxypyrene-1,3,6-trisulfonic acid trisodium salt, suitable for fluorescence, ≥90% (HPCE)
Sigma-Aldrich
Anti-MLL/HRX Antibody, CT., clone 9-12, clone 9-12, Upstate®, from mouse
Sigma-Aldrich
CPNQ, ≥98% (HPLC), solid
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Setd7
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Mll1
Sigma-Aldrich
MISSION® esiRNA, targeting human SETD7